The 8,000ft² facility is designed for developing new products as well as providing customer training to support commercialization of the company’s novel truFreeze Spray Cryotherapy system that flash freezes and ablates unwanted tissue inside the body.
CSA Medical president and chief executive officer Bill Floyd said throughout this year, the company has achieved critical milestones associated with introducing its FD-cleared truFreeze technology to the market.
"Along the way, executives from leading global medical device companies have joined the CSA Medical leadership team in the Boston area to advance the development of our technology," Floyd added.
"We believe this additional facility and desirable location will enable us to continue to attract and retain a highly-skilled staff of engineers, clinical, regulatory and business professionals to help bring the benefits of spray cryotherapy to more patients."
